With news that an Aussie Flu is affecting the UK population and that a Swine flu is ravishing India, it is by no coincidence that a new patent has been granted for a `UNIVERSAL` Flu vaccine.
The patent was given by the Indian Government to Pharmaceutical company on 2nd January 2018.
It involves BiondVax which was created by the Israelis. https://www.timesofisrael.com/biondvax-surges-after-results-of-flu-vaccine-study/
Dr. Tamar Ben-Yedidia, CSO of BiondVax, commented, “We are pleased and thankful that the Government of India’s Patent Office accepted the uniqueness of our universal flu vaccine solution and approved this main patent of BiondVax. Authorities worldwide recognise that currently marketed influenza vaccines fall short. I am proud that M-001, which is designed to cover current, future, seasonal and pandemic flu strains, is preparing to enter Phase 3 trials later in 2018.”
It is also reported that the vaccine will be in use in 30 countries.
On August 31, 2017, BiondVax announced its intent to voluntarily delist from the Tel Aviv Stock Exchange (TASE): Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange
On October 30, 2017, BiondVax announced the last trading date on TASE will be January 18, 2018, and that shares will be delisted from the TASE on January 22, 2018. This announcement was filed with the TASE http://maya.tase.co.il/reports/details/1128530/1/0 and the SEC https://www.sec.gov/Archives/edgar/data/1611747/000121390017011053/f6k103017_biondvaxpharma.htm.
The company announced in August 2017 that it will delist from the stock exchange January 2018. Delisting usually means that they have been bought out by a private equity firm.
BiondVax Meets with the US Biomedical Advanced Research and Development Authority (BARDA) to Present the Use of its Universal Flu Vaccine against Global Pandemic Influenza Outbreak
Nes Ziona, Israel – February 26, 2014 – BiondVax Pharmaceuticals Ltd (TASE: BNDX), developer of a universal flu vaccine, announced today that the Company has just returned from a meeting with officials at the Biomedical Advanced Research and Development Authority/Health and Human Services (BARDA/HHS) at which clinical trial results for BiondVax’s universal flu vaccine, the Multimeric 001, was presented. BiondVax was invited to give this seminar to the Influenza Division at BARDA, during which the Company’s solution for global pandemic flu outbreaks was discussed. At the meeting the Company was informed that BARDA will consider proposals to provide pandemic vaccines and funding of clinical trials examining the usage of BiondVax’s universal flu vaccine as a primer that provides preparedness ahead of pandemic flu outbreaks. In addition, at the seminar the Company discussed the use of its vaccine as a standalone universal flu vaccine.http://www.biondvax.com/2014/02/biondvax-meets-with-the-us-biomedical-advanced-research-and-development-authority-barda-to-present-the-use-of-its-universal-flu-vaccine-against-global-pandemic-influenza-outbreak/
And before any Safety trails begin?
Nes Ziona, Israel – February 10th , 2014 – BiondVax (TASE: BNDX), developer of a universal flu vaccine, announced receiving approval from Hong Kong’s patent office to register its patent concerning Multimeric Multiepitopes for the Company’s universal flu vaccine, as well as an approval from the US patent office for the completion of the testing process for patent registration. As part of the US registration process, the patent was found eligible and currently is pending fees. The patent addresses the vaccine structure and composition as well as the manufacturing methods and the usages of the universal flu vaccine, while providing scope for possible changes in the structure of the protein that is the basis for the universal vaccine. The patent extends and secures the coverage provided by existing patents that protect BiondVax’s intellectual property.
These approvals in Hong Kong and the US build on patent approvals already received in Australia, China, Russia and Mexico. In parallel, the Company is in the process of registering the patent in other locations worldwide such as Europe and Israel. http://www.biondvax.com/2014/02/biondvax-receives-patent-registration-approval-for-multimeric-multiepitope-influenza-vaccines-in-hong-kong-as-well-as-allowance-of-patent-registration-in-us-for-the-companys-universal-flu-vac/
Reports even claim that it can cover strains which do not exist!
Ness Ziona, Israel – January 12, 2017
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, reports the publication this week of an article titled, “Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain” in the prestigious peer-reviewed scientific journal Vaccine.
Dr. Tamar Ben-Yedidia, BiondVax’s Chief Scientist and co-inventor of M-001, commented, “We consider this study to provide validation of M-001’s potential. It is a promising indication that our vaccine may provide improved protection against future flu strains, including potentially pandemic strains that don’t yet exist!” http://www.biondvax.com/2017/01/back-to-the-future-study-published-in-vaccine-journal-indicates-biondvaxs-universal-flu-vaccine-candidate-may-cover-strains-which-dont-yet-exist/
So there we have it! A miracle vaccine that was granted patents even before it was tested, that can cure all strains of flu world wide, even those that do not yet exist and is being stockpiled for the next pandemic!